Actively Recruiting
Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)
Led by Imperial College London · Updated on 2026-03-30
1263
Participants Needed
12
Research Sites
418 weeks
Total Duration
On this page
Sponsors
I
Imperial College London
Lead Sponsor
Q
Queen Mary University of London
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)? Patients will be allocated in a 1.1 ratio to either MRI scans or the current NICE defined standard. Randomisation will be blocked (random block size) and stratified by MRI visibility of lesions (3 categories \[ no visible lesion, diffuse changes, discrete visible lesion\]), cancer Grade Group (GG1, GG2) and time since diagnosis. This study will not be blinded to patients or physicians.
CONDITIONS
Official Title
Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or above (no upper limit)
- Patients with a prostate (cis-male or trans-female with no prior androgen deprivation hormone use)
- Diagnostic bi-parametric or multiparametric MRI performed
- Diagnostic systematic biopsy with or without targeted biopsy
- Histological diagnosis of localized prostate cancer
- Patient has chosen active surveillance
You will not qualify if you...
- On active surveillance for more than 9 months before screening
- Contraindication to MRI or gadolinium contrast
- Previous hip replacement in both hips
- Contraindication to biopsy performed with a transrectal ultrasound probe
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Heatherwood Hospital
Ascot, Berkshire, United Kingdom, SL5 7GB
Actively Recruiting
2
Darent Valley Hospital
Dartford, Kent, United Kingdom, DA2 8DA
Actively Recruiting
3
Bradford Royal Infirmary
Bradford, United Kingdom
Actively Recruiting
4
St Peter's Hospital
Chertsey, United Kingdom
Actively Recruiting
5
Charing Cross Hospital
London, United Kingdom, W6 8RF
Actively Recruiting
6
Kings College London
London, United Kingdom
Actively Recruiting
7
West Middlesex Hospital
London, United Kingdom
Actively Recruiting
8
Freeman Hospital
Newcastle upon Tyne, United Kingdom
Actively Recruiting
9
Glan Clywd Hospital
Rhyl, United Kingdom
Actively Recruiting
10
Northern Lincolnshire and Goole NHS Foundation Trust
Scunthorpe, United Kingdom
Actively Recruiting
11
Southampton University Hospital
Southampton, United Kingdom
Actively Recruiting
12
North Cumbria
Whitehaven, United Kingdom
Actively Recruiting
Research Team
H
Hashim Ahmed
CONTACT
I
Increase Akinyemi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here